Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/jcm10040783 http://scihub22266oqcxt.onion/10.3390/jcm10040783 33669218!7919806!33669218     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Med 2021 ; 10 (4): ä Nephropedia Template TP {{tp|p=33669218|t=2021. The Rheumatology Drugs for COVID-19 Management: Which and When?|pdf=|usr=}}{{33669218}} gab.com Text The Rheumatology Drugs for COVID-19 Management: Which and When JO: J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=33669218 #FOAvip While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1beta, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-alpha, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients. Twit Text FOAVip The Rheumatology Drugs for COVID-19 Management: Which and When ????J Clin Med http://www.kidney.de/pget.php?&tw=1&pmid=33669218 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33669218 #FOAvip English Wikipedia <ref>{{Cite pmid|33669218}}</ref> The Rheumatology Drugs for COVID-19 Management: Which and When? #MMPMID33669218 Atzeni F; Masala IF; Rodriguez-Carrio J; Rios-Garces R; Gerratana E; La Corte L; Giallanza M; Nucera V; Riva A; Espinosa G; Cervera R J Clin Med 2021[Feb]; 10 (4): ä PMID33669218show ga While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1beta, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-alpha, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients. äThe Rheumatology Drugs for COVID-19 Management: Which and When?(epmc).pdf DeepDyve Pubget Overpricing